Symptomatic benign prostatic hyperplasia: the role of 5-alpha-reductase inhibitors in the prevention of acute urinary retention and surgical therapy
Benign prostatic hyperplasia (BPH) is a disease that affects over 50% of males aged 50 years or older. In men aged >80 years, the incidence is 90%. BPH occurs in 9-25% of males aged 40 to 79 years. Fifty percent of patients with BPH are symptomatic. The symptoms include reduced urinary fl...
Main Authors: | Norma Marigliano, Domenico Galasso |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2012-01-01
|
Series: | Italian Journal of Medicine |
Subjects: | |
Online Access: | http://www.italjmed.org/index.php/ijm/article/view/69 |
Similar Items
-
Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
by: Mariana Escamilla-Cruz, et al.
Published: (2023-07-01) -
Persistent Erectile Dysfunction after Discontinuation of 5-Alpha Reductase Inhibitor Therapy in Rats Depending on the Duration of Treatment
by: Hyun Hwan Sung, et al.
Published: (2019-05-01) -
Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection
by: Juan Morote, et al.
Published: (2024-02-01) -
Finasteride therapy in a dog with benign prostatic hyperplasia
by: Hyejin Kim
Published: (2022-09-01) -
A comparative study of fixed dose of Tamsulosin with finasteride vs Tamsulosin with dutasteride in the management of benign prostatic hyperplasia
by: N K Mohanty, et al.
Published: (2006-01-01)